Searched for
JANUMET
TrumpRx explained: How Trumpâs new drug price deals with 9 pharma companies could save patients moneyTrumpRx: President Donald Trump has struck new deals with nine major drug companies. These agreements aim to reduce prescription drug price...- Abbott asks stockists to buy only from authorised suppliersSpurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized ...
- Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in IndiaAbbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin...
- Pricing authority caps rates of key diabetes drugsIndia’s drug pricing authority has fixed prices of two key anti diabetes drugs-Sitagliptin-Metformin combination and Linagliptin-metformin ...
- Generics of MSD diabetes pill set to flood market as patent expiresAccording to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...
- Domestic pharma retail market grows 13% in JulyAnti-diabetic therapy dominated the pecking order with four of the top 10 brands, Galvus MET and Janumet being the other top grossers.
- Glenmark evaluating legal options over diabetes drugs setbackGlenmark said it is evaluating legal options after the Delhi HC restrained it from manufacturing & selling generic version of MSD's anti-di...
- Blow to Glenmark: Delhi High Court restrains it from making Zita & Zita-MetHC restrained Glenmark from making, selling, advertising, distributing or exporting its anti-diabetes drugs Zita and Zita-Met.
- Glenmark's anti-diabetes drugs shake up Indian anti-diabetes marketThe company has raked in Rs 16 crore in just 8 months since drug was launched.
- MSD-Glenmark drug patent row: Delhi High Court reserves verdictThe Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.
- Patent row: Merck gets interim relief from HCThe Delhi High Court has restrained an Indian pharmaceutical company from launching its diabetes drug manufactured by Merck Sharp and Dohme...
- US drugmaker MSD gets interim relief on diabetes drug patent rowThe US pharma major alleged the Indian company was coming out with the diabetes drug with Sitagliptin molecule and its derivatives salt in ...
- Delhi High Court seeks Glenmark's response on US drug giant MSD's appealJustice S Ravindra Bhat and SK Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the sing...
- Drug patent row: Delhi High Court seeks Glenmark's response by May 22The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation o...
- Drug patent row: HC to hear plea of US firm on April 12A bench of justices Sanjay Kishan Kaul and Indermeet Kaur took the plea of US pharma major on record and posted it for hearing before anoth...
- Drug patent row: Merck Sharp and Dohme files appeal against interim order in row with GlenmarkMSD has filed an appeal before the Delhi HC challenging its single bench order refusing to grant interim relief to it on a patent row again...
- No interim relief to Merck against Glenmarkâs diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...
- Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugsA unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
Load More
